Unveiling 4 Analyst Insights On Viridian Therapeutics
Portfolio Pulse from Benzinga Insights
Viridian Therapeutics (NASDAQ:VRDN) has been the subject of analysis by 4 analysts over the past three months, with ratings ranging from bullish to somewhat bullish. The average 12-month price target for VRDN is $34.25, with a high of $40.00 and a low of $30.00, reflecting a slight decrease of 0.72% in sentiment. The company, a clinical-stage biopharmaceutical firm focusing on thyroid eye disease treatments, has seen a -31.43% decline in revenue growth and faces challenges in profitability and asset utilization.
March 20, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Viridian Therapeutics has received mixed analyst ratings, with a slight negative adjustment in the average price target. The company's financial performance shows significant challenges, including a sharp decline in revenue and issues with profitability and asset utilization.
The decrease in the average price target, combined with the company's reported decline in revenue and challenges in maintaining profitability and efficiently utilizing assets, suggests a negative short-term impact on VRDN's stock price. Analysts' mixed ratings and the slight negative sentiment adjustment further contribute to this outlook.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100